Skip to main content

Drug Interactions between Prempro and succinylcholine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

succinylcholine conjugated estrogens

Applies to: succinylcholine and Prempro (conjugated estrogens / medroxyprogesterone)

MONITOR: The neuromuscular blocking effect of succinylcholine may be potentiated by chronic administration of estrogens or high-dose corticosteroids. Available data suggest that steroids may reduce plasma cholinesterase activity, resulting in decreased metabolic clearance of succinylcholine. There have been isolated case reports of patients treated with estrogen-containing products such as estradiol and diethylstilbestrol who experienced prolonged apnea or muscle paralysis following succinylcholine administration. Laboratory testing demonstrated reduced serum pseudocholinesterase activity in these patients. One study conducted in 33 women of childbearing age reported significantly reduced serum cholinesterase levels after one month of treatment with various oral contraceptives, with no further reductions after three months. Another 33 women in the same study who had been taking oral contraceptives for at least one year exhibited similarly reduced levels of serum cholinesterase.

MANAGEMENT: Patients receiving chronic therapy with estrogens or corticosteroids should be monitored for increased or prolonged neuromuscular blockade when succinylcholine is administered. A lower initial dosage of succinylcholine may be required.

References

  1. (2022) "Product Information. Quelicin Chloride (succinylcholine)." Hospira Inc
  2. (2022) "Product Information. Anectine (succinylcholine)." Sandoz Inc
  3. (2022) "Product Information. Suxamethonium Chloride (suxamethonium)." Advanz Pharma
  4. (2021) "Product Information. Suxamethonium (Accord) (suxamethonium)." Accord Healthcare Pty Ltd, 1.0
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Minor

conjugated estrogens food

Applies to: Prempro (conjugated estrogens / medroxyprogesterone)

Coadministration with grapefruit juice may increase the bioavailability of oral estrogens. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits. In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%. Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol. However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability. Also, the effect on other estrogens has not been studied.

References

  1. Weber A, Jager R, Borner A, et al. (1996) "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception, 53, p. 41-7
  2. Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T (1995) "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet, 20, p. 219-24

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.